Skip to main content
. Author manuscript; available in PMC: 2024 Nov 2.
Published in final edited form as: Cancer Immunol Res. 2024 May 2;12(5):544–558. doi: 10.1158/2326-6066.CIR-23-0873

Figure 6. Spatial features of T cells associated with anti-CD40 therapy and prolonged DFS in the PDAC TME.

Figure 6.

A. T cell subsets that best define resected tumor samples from treatment-naive (left) or anti-CD40-treated (right) patients. In the absence of therapy, T cells appear in an exhausted state, while T cells present with activated and effector phenotypes after CD40 agonism. Created with BioRender.com.

B. T cell phenotypes in IAs from anti-CD40-treated patients associated with long (top) or short (bottom) DFS. IAs from patients with long DFS are characterized by the presence of spatial neighborhoods of effector T cells capable of proliferating and cytotoxicity, while IAs from patients with short DFS have a preponderance of exhausted T cell states. Created with BioRender.com.